Curriculum Vitae - UNC Gillings School of Global Public Health

Transcripción

CURRICULUM VITAE
Ramón Bataller, M.D.
Personal Data:
Citizenship:
Spain
Business Address:
2209 McGavran-Greenberg
University of North Carolina at Chapel Hill
C.B. # 7461
Chapel Hill, NC 27599-7461
Languages:
Catalan, Spanish, English, Italian
Education:
High School: Colegio Maristas, Valencia, Spain
University of Valencia School of Medicine, Valencia, Spain, 1984-1990.
Professional Experience:
Resident, Liver and Gastroenterology Units, Hospital Clínic, Barcelona, 1991-1994.
Faculty member, Emergency Room, Hospital Clínic, Barcelona, 1994-1998.
Research Fellow, Liver Unit, Hospital Clínic, Barcelona, 1995-2000.
Visiting Fellow, Università degli Studi di Firence, Florence, Italy, 1995.
Visiting Fellow, Free University of Brussels, Brussels, Belgium, 1997.
Postdoctoral Fellow, University of North Carolina at Chapel Hill, 2000-2003.
Senior Especialist, Liver Unit, Hospital Clínic, Barcelona, 2003-2011
Associate Porfessor, UNC Chapel Hill, 2011-present
Board Certified:
Diplomate of Spanish Board of Gastroenterology, 1995.
Societies:
Member, Asociación Española para el Estudio del Hígado.
Member, European Association for the Study of Liver Diseases (EASL).
Member of the Scientific Committee, Governing Board, EASL (2009-2011)
Member, International Society for Research of Hepatic Sinosoid (ISRHS)
Editorial Board
Gastroenterology (2007-2010)
World Journal of Gastroenterology (2006-)
Gut (Associate Editor 2008-2011)
Gastroenterology Research and Practice (2009-)
Research Interests:
Pathogenesis and treatment of hepatic fibrosis.
Alcohol-induced liver disease.
Nonalcoholic steatohepatitis.
PUBLICATIONS
Original articles:
1.- Bataller Sifre R, Gómez García MA, Ferrandis Borrás S, Bataller R, Bataller Alberola RB y
Alberola García MD. Replicación viral, daño histológico y movimiento enzimático en
hepatopatías crónicas por virus B. Rev Esp Enf Digest 1989;6: 537-543.
2.- Bataller R, Llach J, Salmerón JM, Elizalde JI, Mas A, Piqué JM, Brullet E, Terés J, Bordas
JM, Rodés J. Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the MalloryWeiss syndrome. Am J Gastroenterol 1994;89:112-116.
3.- Bataller Sifre R, Roselló Morera J, Bataller R, Ferrández Izquierdo A, Castillo Pallarés J,
Bort Martí J, Galindo Puerto MJ. Correlación del cociente hígado/bazo isotópico con el daño
hístico en hepatopatías crónicas difusas. Rev Esp Enf Digest 1994; 86:651-654.
4.- Elizalde JI, Llach J, Bordas JM, Bataller R, Mondelo F, Panés J, Terés J. Valor del control
endoscópico tras escleroterapia por lesión péptica gastroduodenal. Gastroenterol Hepatol
1994;17:11-13.
5.- Nieto I, Llach J, Bordas JM, Mondelo F, Elizalde JI, Bataller R, Terés J. Hallazgos
endoscópicos gastrointestinales en pacientes infectados por el virus de la inmunodeficiencia.
Gastroenterol Hepatol 1995;18:57-60.
6.- Saló J, Ginès A, Anibarro L, Jiménez W, Bataller R, Clària J, Ginès P, Rivera F, Arroyo V,
Rodés J. Effect of upright posture and physical exercise on endogenous neurohormonal
2
systems in cirrhotic patients with sodium retention and normal supine plasma renin,
aldosterone and norepinephrine levels. Hepatology 1995;22:479-487.
7.- Saló J, Ginès A, Quer JC, Planas R, Ginès P, Bataller R, Jiménez W, FernándezEsparrach G, Arroyo V, Rodés J. Renal and neurohormonal changes following simultaneous
administration of systemic vasoconstrictors and renal vasodilators in patients with hepatorenal
syndrome. J Hepatol 1996;25: 916-923.
8.- Saló J, Jiménez W, Kuhn M, Ginès A, Ginès P, Fernández-Esparrach G, Angeli P, Clària J,
Bataller R, Arroyo V, Forssmann WG, Rodés J. Urinary excretion of urodilatin in patients with
cirrhosis. Hepatology 1996;24:1428-1432.
9.- Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R,
Planas R, Jiménez W, Arroyo V, Rodés J. Renal and neurohormonal changes following
simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in
cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-923.
10.- Bordas JM, Elizalde I, Llach J, Mondelo F, Bataller R, Teres J. Biliary reflux due to
sphincter of Oddi ablation: a new pathogenetic explanation for long-term major biliary
symptoms after endoscopic-sphincterotomy. Endoscopy 1996;28:642-646
11.- Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M,
Pardo A, Castells A, Cabré E, Arroyo V, Gasull MA, Rodés J. Spontaneous bacterial peritonitis
in cirrhotic patients undergoing selective intestinal decontamination. A retrospective study of
229 spontaneous bacterial peritonitis episodes. J Hepatol 1997; 26:88-95.
12.- Bataller R, Nicolás JM, Ginès P, Esteve A, Görbig MN, García-Ramallo E, Pinzani M,
Jiménez W, Ros J, Jiménez W, Thomas A, Arroyo V, Rodés J. Arginine vasopressin induces
contraction and stimulates growth in cultured human hepatic stellate cells. Gastroenterology
1997;113:615-624.
13.- Saló J, Guevara M, Fernández-Esparrach G, Bataller R, Ginès A, Jiménez W, Ginès P,
Rivera F, Arroyo V, Rodés J. Impairment of renal function during moderate physical exercise in
cirrhotic patients with ascites. Relationship with the activity of neurohormonal systems.
Hepatology 1997;25:1338-1342.
3
14.- Saló J, Ginès A, Ginès P, Piera C, Jiménez W, Guevara M, Fernández-Esparrach G, Sort
P, Bataller R, Arroyo V, Rodés J. Effect of therapeutic paracentesis on plasma volume and
transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997;27:645-653.
15.- Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, Bataller
R, Bosch J, Arroyo V, Rivera F, Rodés J. Increased adrenomedullin levels in cirrhosis:
relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology
1998;114:336-343.
16.- Guevera M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, Jiménez W,
Arroyo V, Rodés J. Increased cerebral resistance in cirrhosis: relationship with reninangiotensin and central nervous systems. Hepatology 1998;28:39-44.
17.- Bataller-Sifre R, Bataller R. Aclaramiento de ácido glicocólico en la Enfermedad de
Gilbert. An Med Intern 1998;15:580-583.
18.- Bataller R, Nicolás JM, Ginès P, Görbig MN, García-Ramallo E, Tobías E, Pinzani M,
Lario S, Thomas AT, Arroyo V, Rodés J. Contraction of cultured human stellate cells activated
in culture: a role for voltage-operated calcium channels. J Hepatol 1998; 29:398-408.
19.- Görbig MN, Ginès P, Bataller R, Nicolás JM, Garcia-Ramallo E, Clària J, Arroyo V, Rodés
J. Atrial natriuretic factor inhibits endothelin-induced calcium increase and cell contraction in
human cultured hepatic stellate cells. Hepatology 1999;30:501-509.
20.- Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Bosch J, Arroyo V, Rodés
J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells.
Gastroenterology 2000;118:1149-1156.
.
21.- Titos E, Clària J, Bataller R, Bosch-Mercé M, Ginès P, Jiménez W, Arroyo V, Rivera F,
Rodés J. Mechanisms of increased hepatic cysteinyl-leukotriene production in experimental
cirrhosis. Gastroenterology 2000;119:794-805.
22.- Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A,
Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy
for hepatorenal syndromeHepatorenal syndrome. J Hepatol 2000; 33:43-48.
4
23.- Llovet JM, Moitinho E, Sala M, Bataller R, Rodriguez-Iglesias P, Castells A, Fernandez J,
Planas R, Navasa M, Bruix J, Rodes J. Prevalence and prognostic value of hepatocellular
carcinoma in patients presenting with spontaneous bacterial peritonitis. J Hepatol 2000;
33:423-429.
24.- Nicolás JM, Fernández-Solà J, Fatjó R, Casamitjana R, Bataller R, Sacanella E, Tobías
E, Badía E, Estruch R. Increased circulating leptin levels in chronic alcoholism. Alcohol Clin
Exp Res 2001; 25:83-88.
25.- Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quinto L, Ventura PJ,
Cardenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic
model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
26.- Görbig MN, Ginès P, Bataller R, Nicolás JM, García-Ramallo E, Cejudo P, Sancho-Bru P,
Jiménez W, Arroyo V, Rodés J. Human hepatic stellate cells secrete adrenomedullin: potential
autocrine factor in the regulation of cell contractility. J Hepatol 2001; 34:222-229.
27.- Bataller R, Gasull X, Ginès P, Hellemans K, Görbig MN, Nicolás JM, Sancho-Bru P, De
las Heras D, Gual A, Geerts A, Arroyo V, Rodés J. In vitro and in vivo activation of rat hepatic
stellate cells results in de novo expression of L-type voltage-operated calcium channels.
Hepatology 2001; 33:956-962.
28.- Gasull X, Bataller R, Ginès P, Sancho-Bru P, Nicolás JM, Görbig MN, Ferrer E, Badía E,
Gual A, Arroyo V, Rodés J. Human myofibroblastic hepatic stellate cells express Ca2+activated K+ channels that modulate the effects of endothelin-1 and nitric oxide. J Hepatol
2001;35:739-748.
29.- Uriz J, Gines P, Ortega R, Jimenez W, Cardenas A, Calahorra B, Sort P, Fernandez J,
Bataller R, Arroyo V, Rivera F, Rodes J. Increased plasma levels of neuropeptide Y in
hepatorenal syndrome. J Hepatol 2002;36:349-55.
30.- Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M,
Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for
patients with hepatorenal syndrome: Results of a prospective, nonrandomized study.
Hepatology 2002;36:941-948.
5
31.- Paik YH, Schwabe R, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4
mediates inflammatory effects by bacterial lipopolysaccharide in activated human hepatic
stellate cells. Hepatology 2003;37:1043-1055.
32.- Bataller R, Ginès P, Sancho-Bru P, Lora JM, Al-Garawi A, Solé M, Nicolás JM, Jiménez
JM, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells
express the components of the renin-angiotensin system and synthesize angiotensin II.
33.- De las Heras D, Fernandez J, Gines P, Cardenas A, Ortega R, Navasa M, Barbera JA,
Calahorra B, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J. Increased carbon
monoxide production in
patients with cirrhosis with and without spontaneous bacterial
peritonitis. Hepatology 2003;38:452-459.
34.- Bataller R, Gabele E, Ling Y, Schoonhoven R, Brenner DA, Rippe RA. Prolonged infusion
of angiotensin II into normal rats induces hepatic stellate cells activation and proinflammatory
events in the liver. Am J Physiol 2003; 285:G642-G651.
35.- Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R,
Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in
hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-1394.
36.- Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and
RANTES to induce proliferation and migration. Am J Physiol 2003;285:G949-G958.
37.- Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts
with endoplasmic reticulum Ca++ pump SERCA 2b and is necessary for collagen type I
synthesis. Mol Cell Biol 2004;24:1758-1768.
38.- Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and
nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology
2004;126:529-540.
6
39.- Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse
demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:11511159.
40.- Gabele E, Reif S, Tsukada S, Bataller R, Yata Y, Morris T, Schrum LW, Rippe RA. The
role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol
Chem 2005;280:13374-13382.
41.- Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, Rippe
RA. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct ligated rats.
Hepatology 2005; 41:1046-1055.
42.- Yang L, Bataller R, Dulyx J, Coffman TM, Rippe RA, Ginès P, Brenner DA. Attenuated
hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005
43:317-323.
43.- Sancho-Bru P, Bataller R, Gasull X, Colmenero J, Khurdayan V, Gual A, Nicolás JM,
Arroyo V, Rodés V. Genomic and functional characterization of stellate cells isolated from
human cirrhotic livers. J Hepatol 2005;43:272-282.
44.- Yang L, Magness ST, Bataller R, Rippe RA, Brenner DA. NF-kB activation in Kupffer cells
after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol. 2005;289:G530-8.
45.- Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, Arroyo V, Brenner DA,
Ginès P. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic
stellate cells. Am J Physiol Gastrointest Liver Physiol 2006;291:G877-G884.
46.- Bertolami C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B,
Romagnani P, Milani S, Ginès P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G,
Pinzani M, Marra F. Resistin as an intrahepatic cytokine: overexpression during chronic injury
and induction of pro-inflammatory actions in hepatic stellate cells . Am J Pathol 2006;169:20422053.
47.- Colmenero J, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, Bosch J, Arroyo V,
Caballería J, Ginès P. Hepatic Expression of Candidate Genes in Patients with Alcoholic
Hepatitis: correlation with Disease Severity. Gastroenterology 2007; 132:687-697.
7
48.- Fatjó F, Sancho-Bru P, Fernández-Solà J, Sacanella E, Estruch R, Bataller R, Nicolás JM.
Up-Regulation of Myocardial L-Type Ca(2+) Channel in Chronic Alcoholic Subjects Without
Cardiomyopathy. Alcohol Clin Exp Res 2007;31:1099-1105.
48.- Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A.
Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in nontransplanted patients with chronic hepatitis C. Liver Transpl 2007;13:1017-1027.
49.- Sancho-Bru P, Bataller R, Fernandez-Varo G, Moreno M, Ármalo LN, Colmenero J, Marí
M, Joan Clària J, Jiménez J, Arroyo V, Brenner DA, Ginès P. Bradykinin attenuates
hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology
2007;133(6):2019-2028.
50.- Rodríguez-Vilarrupla A, Graupera M, Matei V, Bataller R, Abraldes JG, Bosch J, GarcíaPagán JC. Large-conductance calcium-activated potassium channels modulate vascular tone
in experimental cirrhosis. Liver Int. 2008;28:566-573.
51.- Botella-Lopez A, de Madaria E, Jover R, Bataller R, Sancho-Bru P, Candela A, Compañ
A, Pérez-Mateo M, Martinez S, Sáez-Valero J. Reelin is overexpressed in the liver and plasma
of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with
cirrhosis. Int J Biochem Cell Biol 2008;40:766-75.
52.- Domínguez M, Rincón D, González-Abraldes J, Miquel R, Colmenero J, Bellot P, GarcíaPagan JC, Fernández-Caspistrán R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P,
Bataller R. A new scoring system allows prognostic stratification in patients with alcoholic
hepatitis. Am J Gastroenterol 2008;103:2747-56
53.- Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG,
Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates
angiotensin II-induced inflammatory and pro-fibrogenic actions in the liver. Am J Physiol
2009;296:G147-56.
54.- Ferré N, Martínez-Clemente M, López-Parra M, González-Périz A, Horrillo R, Planagumà
A, Camps J, Joven J, Tres A, Guardiola F, Bataller R, Arroyo V, Clària J. Increased
8
susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential
involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009;296:G553-62.
55.- Domínguez M, Miquel R, Colmenero J, Moreno M, García-Pagán JC, Bosch J, Arroyo V,
Gines P, Caballeria J, Bataller R. Hepatic expression of CXC chemokines influence survival
and portal hypertension in patients with alcoholic hepatitis. Gastroenterology 2009;136:163950.
56.- Oakley F, Teoh V, Ching-A-Sue G, Bataller R, Colmenero J, Jonsson JR, Eliopoulos AG,
Watson MR, Manas D, Mann DA. Angiotensin II activates IkappaB kinase phosphorylation of
RelA at Ser536 to promote myofibroblast survival and liver fibrosis. Gastroenterology
2009;136:2334-2344.
57.- Colmenero J, Bataller R, Sancho-Bru P, Dominguez M, Moreno M, Forns X, Bruguera M,
Arroyo V, Brenner DA, Ginès P. Effects of Losartan on Hepatic Expression of Non-phagocytic
NADPH Oxidase and Fibrogenic Genes in Patients with Chronic Hepatitis C. Am J Physiol
Gastrointest Liver Physiol 2009 297:G726-34.
58.- Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J,
Bataller R, Schwabe RF. Modulation of Hepatic Fibrosis by c-Jun-N-terminal Kinase Inhibition.
59.- Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J,
Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K,
Brenner DA, Ginès P, Bataller R. Reduction of advanced liver fibrosis by targeted delivery of
an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51:942-52.
60.- Sancho-Bru P, Juez E, Moreno M, Khurdayan V, Morales-Ruiz M, Colmenero J, Arroyo V,
Brenner DA, Ginès G, Bataller R. Hepatocarcinoma cells stimulate growth, migration and
expression of pro-angiogenic genes in human hepatic stellate cells. Liver International
2010;30:31-41.
61.- Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C,
Dominguez M, Conde L, Millán C, Marí M, Colmenero J, Lozano JJ, Jares P, Vidal J, Forns X,
Arroyo V, Caballería J, Ginès P, Bataller R. Ghrelin attenuates hepatocellular injury and liver
9
fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology
2010;51:974-85.
62.- Azzalini L, Ferrer E, Ramalho LN, Moreno M, Domínguez M, Colmenero J, Peinado VI,
Barberà JA, Arroyo V, Ginès P, Caballería J, Bataller R. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology 2010;51:1567-76.
63.- Albillos A, Nieto M, Ubeda M, Muñoz L, Fraile B, Reyes E, Lledó L, Blanco I, Pastor O,
Salas C, Lario M, Monserrat J, Bataller R, Álvarez-Mon M. The biological response modifier
AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis.
Gut 2010;59:943-52.
64.- Moles A, Tarrats N, Morales A, Domínguez M, Bataller R, Caballería J, García-Ruiz C,
Fernández-Checa JC, Marí M. Acidic sphingomyelinase controls hepatic stellate cell activation
and in vivo liver fibrogenesis. Am J Pathol 2010;177:1214-24.
65.- Ki SH, Park O, Zheng M, Kolls J, Morales-Ibanez O, Bataller R, Gao B. Interleukin-22
treatment ameliorates alcoholic liver injury in a murine model of chronic plus binge ethanol
feeding: Role of STAT3. Hepatology 2010;52:1291-300.
66.- Melgar-Lesmes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, Morales-Ruiz M,
Jimenez W. Apelin mediates the induction of profibrogenic genes in human hepatic stellate
cells. Endocrinology 2010;151:5306-14.
67.- Steenkiste CV, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier
K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M,
Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I,
Morales-Ruiz M. Inhibition of placental growth factor activity reduces the severity of fibrosis,
inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011;53:1629-40.
68.- Altamirano J, Higuera-de laTijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG,
Herrera-Jimenez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González
JA, Dominguez M, Arroyo V, Gines P, Caballería J, Bataller R. The amount of alcohol
consumption negatively impacts short-term mortality in hispanic patients with alcoholic
hepatitis. Am J Gastroenterol 2011;106:1472-80.
10
69.- Melgar-Lesmes P, Pauta M, Reichenbach V, Casals G, Ros J, Bataller R, Morales-Ruiz M,
Jiménez W. Hypoxia and proinflammatory factors upregulate apelin receptor expression in
human stellate cells and hepatocytes. Gut 2011;60:1404-11.
70.- Altamirano J, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, Guevara M,
Pereira G, Torres-Vigil K, Arroyo V, Caballería J, Ginès P, Bataller R. Acute kidney injury is an
early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol
2012;10:65-71.
71.- Altamirano J, Bataller R, Cardenas A, Michelena J, Freixa N, Monrás M, Ríos J, Liccioni
A, Caballería J, Gual A, Lligoña A. Predictive factors of abstinence in patients undergoing liver
transplantation for alcoholic liver disease. Ann Hepatol 2012;11:213-21.
72.- Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, Yin S, Gao P, Shan X,
Pickel J, Bataller R, O'hare J, Scherer T, Buettner C, Kunos G. Hepatic Cannabinoid Receptor1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in
Mice. Gastroenterology 2012;142:1218-28.
73.- Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millán C, José Lozano J, Miquel R,
Arroyo V, Caballería J, Ginès P, Bataller R. Liver progenitor cell markers correlate with liver
damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012
(in press).
74.- Affo, S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O,
Moreno M, Millan C, Loaeza-del-Castillo A, Altamirano J, Garcia-Pagan JC, Arroyo V, Gines P,
Caballeria J, Bataller R. Transcriptome Analysis Identifies Fn14, a TNF Superfamily Receptor,
as a Therapeutic Target in Alcoholic Hepatitis. Gut 2012 (in press).
Case reports:
1.- Bataller-Sifre R, Peydró A, Arroyo M, Bataller R, Carda C, Broseta R. Determinación de
cobre en tejido hepático para el diagnóstico de la Enfermedad de Wilson. An Med Intern 1989;
6 :145-148.
11
2.- Sierra J, Martí JM, Bataller R, Calvet X, Bru C, Grañena A, Rozman C. Pancreatic
pseudocyst secondary to chemotherapy for acute lymphoblastic leukaemia: successful
percutaneous drainage. Eur J Med 1992; 1:36-371.
3.- Morell M, Ordi J, Bataller R, Trias M, Cardesa A. Pneumatosis cystoides intestinalis en una
paciente con enfermedad de Crohn. Gastroenterol Hepatol 1993;16:67-69.
4.- Elizalde JI, Escorsell A, García-Pugués A, Navarro S, Bataller R, Terés J. Sarcoma de
Kaposi de localización rectal aislada. Rev Esp Enf Digest 1993; 84:399-401.
5.- Bataller R, Urbano-Izpizua A, Luburich P,
Monserrat E,
Rozman C. Masa pulmonar
cavitada como manifestación inicial de la enfermedad de Hodgkin. Med Clin (Barcelona) 1994;
103:342-343.
6.- Elizalde JI, Bataller R, Bruix J, Rodés J. Hepatotoxicidad por propafenona. Gastroenterol
Hepatol 1994; 18(8):382-383.
7.- Bataller R, Bordas JM, Ordi J, Llach J, Elizalde JI, Mondelo F. Upper Gastrointestinal
bleeding: a complication of “inlet patch mucosa” in the upper esophagus. Endoscopy 1995;
27:282-283.
8.- Sánchez A, Bataller R, Ginés A, Bruguera M, Rodés J. Tumor carcinoide con afectación
masiva hepática sin síndrome carcinoide asociado. Gastroenterol Hepatol 1995; 18:468-470.
9.- Andreu V, Bataller R, Caballería J, Rodés J. Eosinophilic pneumonitis due to ranitidine. J
Clin Gastroenterol 1996; 23: 160-162.
10.- López-Boado MA, Rull R, Bataller R, González FX, Bordas JM, Visa J. Neumoperitoneo
asintomático después de una fibrogastroscopia. Rev Esp Enf Digest 1996; 88: 365-367.
11.- Bataller-Sifre R, Vicente R, Llombart A, Carda C, Gabriel F, Bataller R, Galindo J. Déficit
heterozigótico de alfa-1 antitripsina. Presentación de un caso. Gastroenterol Hepatol 1996; 19:
313-316.
12
12.- Bataller R, Salmerón JM, Muñoz JE, Obach V, Elizalde JI, Mas A, Tolosa E, Terés J.
Estenosis pilórica complicada con el síndrome de Wernicke-Korsakoff. Gastroenterol Hepatol
1997; 20: 131-133.
13.- Bataller R, Sans M, Escorsell A, Elizalde JI, Bosch J, Rodés J. Esophageal variceal
bleeding due to hypoplasia of the portal vein in a patient with the Klippel-Trenaunay syndrome.
Am J Gastroenterol 1998; 93: 275-276.
14.- Bataller R, Bragulat E, Nogué S, Görbig MN, Bruguera M, Rodés J. Prolonged cholestasis
due to paraquat poisoning throught skin absorption. Am J Gastroenterol 2000;95:1340-1343.
15.- Altamirano J, Zapata L, Poblano M, Rodríguez A, Camargo L, Martínez B, Bataller R.
Acute pylephlebitis following gastrointestinal infection: an unrecognized cause of septic shock.
South Med J 2010;103:956-959.
16.- Ruiz P, Michelena J, Altamirano J, Miquel R, Moreira L, Cárdenas A, Abraldes JG, Brugera
M, Arroyo V, Ginès P, Caballería J, Bataller R. Hepatic hemodynamics and transient
elastography in alcoholic foamy degeneration: report of 2 cases. Ann Hepatol 2012;11:399-403.
Reviews and editorials:
1.- Bataller Sifre R, Gómez García M, Bataller RB, Bataller R, Alberola García MD. Replicación
viral, daño histológico y movimiento enzimático en hepatopatías crónicas por virus B. Rev Esp
Enf Digest 1989; 75:620-624.
2.- Bataller Sifre R, Bataller R, Baleriola Júlvez J. Hepatomegalia. Medicine (Madrid) 1993;
6:325-330.
3.- Bordas JM, Nieto I, Llach J, Mondelo F, Elizalde I, Bataller R, Landaeta J, Terés J. La
endoscopia digestiva en el síndrome de inmunodeficiencia adquirida. Cir Laparosc Endosc
1994; 1:43-47.
4.- Bataller R. Actitud ante la colestasis crónica. Jano 1995;23:34-37.
5.- Bataller R. Anomalías de la función renal en la cirrosis. Medicine (Madrid) 1996; 7:439-444.
13
6.- Bataller R. Cirrosis hepática: clasificación etiopatogénica, valoración funcional y factores
pronósticos. Medicine (Madrid) 1996; 7:421-426.
7.- Bataller R. La collaborazione scientifica nella Cominutà Europea. Fondazione Italiana per lo
Studio del Fegato 1996: 22-23.
8.- Bataller R. Ascitis. Protocolo terapéutico. Fomeco 1996; 4:208-216.
9.- Bataller R, Ginès P, Arroyo V. Practical recommendations for the treatment of ascites and
its complications. Drugs 1997; 54:571-580.
10.- Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal Syndrome. Semin Liver Dis 1997;
17:233-247.
11.- Bataller R, Arroyo V, Ginès P. Management of ascites in cirrhosis. Gastroenterol Hepatol
1997; 12:723-733.
12.- Bustamante J, Bataller R, Sánchez-Fueyo A. Diagnóstico de la Enfermedad de Wilson.
Gastroenterol Hepatol 1997; 20:510-513.
13.- Bataller R, Arroyo V, Ginès P. Hepatorenal syndrome: definition, pathophysiology, clinical
features and management. Kidney Int 1998; 66:S47-53.
14. Bataller R, Ginès P, Arroyo V, Sort P. The hepatorenal syndrome. Forum (Genova) 1998;
8:62-81.
15.- Planas R, Bataller R, Rodés J. Hepatorenal syndrome. Current Treatment Options in
Gastroenterology. 2000; 3:445-450.
16.- Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis 2000;4:487507.
17.- Cárdenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. Clin Liver Dis
2000;4:447-465.
14
18.- Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin Liver Dis 2001;21:437-451.
19.- Bataller R, Ginès P. Nuevas perspectivas terapeúticas en la fibrosis hepática: bases
patogénicas. Med Clin (Barc) 2002;118:339-346.
20.- Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver
fibrosis: a critical appraisal. Hepatology 2003;37:493-503.
21.- Bataller R. Los polimorfismos genéticos y las enfermedades del hígado. Gastroenterol y
Hepatol 2003;26:307-309.
22. Forns X, Bataller R. Can we identify liver fibrosis in HCV-infected patients without a liver
biopsy? Current Hepatitis Reports 2003:2:145-151.
23.- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
24.- Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrosis: a new role for the reninangiotensin system. Antioxidant Redox Signal 2005:7:1346-1355.
25.- Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study
hepatic fibrosis. Methods Mol Med 2005;117:359-70.
26.- De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or
fibrogenic? Gastroenterology 2006;131:272-275.
27.- Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology
2006;44:1394-1346.
28.- Moreno M, Bataller R. Cytokines and Renin-Angiotensin system signaling in hepatic
fibrosis. Clin Liver Dis 2008;12:825-52.
29.- Lligoña A, Freixa N, Bataller R, Monràs M, Rimola A. Clinical guideline for the evaluation
of liver transplant candidates with addictions. Gastroenterol Hepatol 2009;32:155-61.
30.- Altamirano J, Bataller R. Cigarette smoking and chronic liver diseases. Gut 2010;59:115915
1162.
31.- Morales-Ibanez O, Bataller R. Platelet-derived chemokines: new targets to treat liver
fibrosis ? J Hepatol 2011;54:581-3.
32.- Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic
steatohepatitis. Best Pract Res Clin Gastroenterol 2011;25:231-44.
33.- Affó S, Bataller R. RANTES Antagonism: a Promising Approach to Treat Chronic Liver
Diseases. J Hepatol 2011;55:936-8.
34.- Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets.
35.- Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for
therapy. Nat Rev Gastroenterol Hepatol 2011;8:491-501.
Books
1.- Bataller R, Caballería J (eds). Non Alcoholic Steatohepatitis. Permanyer Publications,
Barcelona, 2007.
Book chapters:
1.- Bataller R, Arroyo V. Tratamiento de la ascitis. In: Esplugues JM, Piqué JM, Ponce J (eds).
Terapéutica Farmacológica de las Enfermedades del Aparato Digestivo. 1st edition. Eunsa,
Pamplona, 1996:275-286.
2.- Arroyo V, Bataller R. Treatment of hepatorenal Syndrome. In: Arroyo V, Ginès P, Rodés J,
Schirer RW (eds). Ascites and Renal Dysfunction in Liver Disease. Blackwell Science, Malden,
1999:3-14.
4.- Arroyo V, Bataller R. Historical notes on ascites. In: Arroyo V, Ginès P, Rodés J, Schirer
RW (eds). Ascites and Renal Dysfunction in Liver Disease. Blackwell Science, Malden, 1999:314.
16
5.- Bataller R, Uriz J. Spontaneous circulatory failure in cirrhosis. Mechanisms and
consequences. In: Arroyo V, et al (eds). Therapy in Liver Diseases, 3th Edition. Masson,
Barcelona, 1999:147-154.
6.- Cárdenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. In: Clinics in Liver
Disease. J.L.Herven. W.B. Saunders Co. Philadelphia 2000:447-466.
7.- Bataller R, Arroyo V. Fracaso renal agudo asociado a enfermedades hepáticas. Síndrome
hepatorenal. In Liaño F, Pascual J. Fracaso renal agudo. Barcelona. Masson. 2000: 103125:313-326
8.- Bataller R, Ginés P, Arroyo V, Rodés J. Hepatorenal syndrome. In: Clinics in Liver Disease.
W.B. Saunders Co. Philadelphia 2000:487-508.
9.- Arroyo V, Bataller R, Ginès P. Ascites and spontaneous Bacterial Peritonitis. In:
Comprehensive Clinical Hepatology. J. O. Grady, J.R. Lake, P.D. Howdle (eds). Mosby. Saint
Louis 2000:7/1-7/14.
10.- Uriz J, Bataller R, Arroyo V. Síndrome Hepatorenal. In: Lovesio C (ed). Medicina
Intensiva. Editorial el Ateneo. Buenos Aires 2001;634-640.
11.- Arroyo V, Cárdenas A, Bataller R. Ascites and spontaneous bacterial peritonitis. In:
Gastroenterologija I Hepatologija. Volume 2. Boris Vucelic I Suradnici (ed). Medicinska
Anclada. Zagreb, 2002:1302-1314.
12.- Arroyo V, Cárdenas A, Bataller R. Renal Complications in Liver DiseaseAscites and
Spontaneous Bacterial Peritonitis. In: Gastroenterologija I Hepatologija. Volume 2. Boris
Vucelic i Suradnici (ed). Medicinska Anclada. Zagreb, 2002:1294-1301.
13.- Bataller R, Sancho-Bru P, Ginès P. The renin-angiotensin system and liver fibrosis:
therapeutical implications. In: Arroyo V, Forns X, García-Pagán JC, Rodés J. Progress in the
Treatment of Liver Diseases. Arts Medica, Barcelona 2003:209-214.
14.- Bataller R, Arroyo V. Ascites. Non-operative management. In: Controversies in Surgery.
Volume 4. Springer-Verlag. Heildelberg 2004.
17
15.- Bataller R, Colmenero J, Sancho-Bru P. Etiology and Pathogenesis. In: Navasa M, Arroyo
V (eds). Liver cirrhosis. Doyma, Barcelona 2005.
16.- Bataller R, Domínguez M, Caballería J. Clinical manifestations and prognosis of NASH. In:
Bataller R, Caballería J (eds). Non Alcoholic Steatohepatitis. Permanyer Publications,
Barcelona, 2007.
17.- Bataller R, Brenner DA. Pathogenesis of Hepatic Fibrosis. In: Yamada T, Alpers DH,
th
Kaplowitz N, Owyang C, Powell DW, Kalloo A (eds). Textbook of Gastroenterology, 5 Edition,
Blackwell Publishing, Oxford England 2007.
18.- Bataller R, Sancho-Bru P. New therapeutical approaches in Hepatology. En: Arroyo V,
Sánchez-Fueto A, Fernández-Gómez J et al et al. Advances in the Therapy of Liver Diseases.
Ars Medica, Barcelona, 2007, 515-522.
19.- Bataller R, Brenner DA. Liver Fibrosis. In: Arias IM, Wolkoff A, Fausto N, Boyer JM,
Shafritz D, Alter H (eds). The Liver: Biology and Pathobiology. Wiley-Blackwell, 2009.
Invited lectures.
1.- Presentación de casos clínicos de Hepatología. III Curso Iberoamericano de Hepatología.
Barcelona, Spain, 1996.
2.- Presentación de casos clínicos de Hepatología. IV Curso Iberoamericano de Hepatología.
3.- "Papel de las células estrelladas hepáticas en la patogenia de la hipertensión portal". VII
Curso de Hepatología, Hospital Reina Sofía. Córdoba, Spain, 1999.
4.- "Spontaneous circulatory dysfunction in cirrhosis. Pathogenesis and consequences", 3rd
International Meeting on Therapy in Liver Diseases. Barcelona, Spain,1999.
5.- “Hepatopatía alcohólica: nuevos avances en la patogenia y tratamiento”. Reunión de la
Sociedad de Gastroenterología de Jalisco, Guadalajara, México, 2000.
6.- “Liver transplantation and hepatic fibrosis”. Transplant Course. University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA, 2002.
18
7.- “Patogenia y tratamiento de la fibrosis hepatica”. Curso de la Asociación Mexicana de
Hepatología, Querétaro, México, 2003.
8.- “Role of the renin-angiotensin system in liver fibrosis”. Meeting on Inflammation and Fibrosis
in the Bowel and the Liver. Chapel Hill, USA, 2003.
9.- “Vasoactive substances: RAS inhibitors”. XXVII Meeting of the European Association of
Gastroenterology. Madrid, Spain, 2003.
10.- “Liver fibrosis in chronic hepatitis C: pathogenesis and treatment”. Frontiers in Hepatology,
Pamplona, Spain, 2003.
11.- “Patogènia i tractament del NASH”. Col.legi de Metges, Barcelona, Spain, 2003.
12.- “NASH: pathogenesis and current therapy”. New Treatments on Obesity, Hospital Clinic,
13.- “Hepatitis C y fibrosis hepática”. II Curso de Hepatología del Hospital de Sant Pau.
14. “Síndrome metabólico y fibrosis hepática”. Cursos de Doctorado, Universitat de Valencia,
Spain, 2005.
15. “Fibrosis hepatica”. LXIV Congreso Anual de la Sociedad Española de Patología Digestiva,
Madrid, Spain, 2005.
16.- “Liver fibrogenesis: pathogenesis and new targets for therapy”. University of Florence,
Italy, 2005.
17.- “Ion fluxes, channels and transporters”. EASL Course in Basic Science, Toscany, Italy,
2006.
18.- “The angiotensinogen pathway”. AASLD Single Topic Conference on Liver Fibrosis.
Washington, 2006.
19
19.- “Role of the Renin-Angiotensin System in Liver Fibrosis”. Brisbane, Australia, 2006.
20. “Fibrosis hepática”. Cursos de Doctorado, Hospital Gregorio Marañón, Spain, 2006.
21.- “Pathogenesis of alcohol-induced liver fibrosis: prospects for therapy”. Sydney, Australia,
2006.
22.- “Renin-angiotensin system signaling and liver fibrosis”. EASL School of Medicine, Lisbon,
Portugal, 2006.
23.- “Liver fibrosis: genetic tests”. 14
th
United European Gastroenterology Week, Berlin,
Germany, 2006.
24.- “Fibrosis hepática: una respuesta regenerativa patológica en las hepatopatías crónicas”.
Real Academia de farmacia, Madrid, Spain, 2006.
25.- “Fisiopatología y tratamiento de la fibrosis hepática”. I Curso de Hepatología. Hospital
Clínic, Barcelona, Spain, 2006.
26.- “Nuevas perspectives terapéuticas en la fibrosis hepática”. Pamplona, Spain, 2007.
27.- “Non-invasive diagnosis of hepatic fibrosis”. Curso conjunto AGA-SEPG, Madrid, Spain,
2007.
28.- “Fibrosis hepática; fisiopatología y tratamiento”. II Curso de Hepatología. Hospital Clínic,
29.- “Futuros tratamientos en hepatología: células madre y farmacogenómica”. Sevilla, Spain,
2007.
30.- “Fibrosis hepática: bases genéticas y nuevas perspectivas terapéuticas”. Santiago de
Chile, Chile, 2007.
31.- “New therapies in hepatology”. V Meeting on Therapies of Liver Diseases, Barcelona,
Spain, 2007.
20
32.- “Pathogenesis of fibrosis in chronic liver diseases”. EASL School of Medicine. Barcelona,
Spain, 2007.
33.- “Fibrosi hepàtica: patogènia, diagnostic no invasiu i noves perspectives terapèutiques”.
Acadèmia de Medicina de Catalunya, Barcelona, Spain, 2008.
34.- “Fibrosis hepática; patogenia y tratamiento”. III Curso de Hepatología. Hospital Clínic,
35.- “Mechasnismos and genetics”. V International Meeting on Immunology and the Liver:
Fibrosis-Mechanisms and Therapies. Madrid 2009.
36.- “Tratamiento de la fibrosis hepática”. XXXIV Congreso de la Asociación Española para el
Estudio de las Enfermedades del Hígado. Madrid, 2009.
37.- “Reactive oxygen species and liver fibrosis”. 19th Conference of APASL, Hong Kong,
2009.
38.- “Recomendaciones actuales para el diagnóstico y tratamiento de la fibrosis hepática”.
Actualizaciones en Hepatología, Aranjuez, Spain, 2009.
39.- ”Alcoholic hepatitis: identification of new targets for therapy”. University of Regensburg,
Germany, 2009.
40.- “Experimental Liver Fibrosis”. University of Sao Paolo at Riberio Preto, Brazil 2010.
41.- “Towards the translation of basic research to clinical solutions for fibrosis”. EASL
International Liver Meeting. Vienna, Austria, 2010.
42.- “New therapeutic targets for alcoholic hepatitis identified in human samples”. ESBRAEASL Joint Meeting, Vienna, Austria, 2010.
43.- “How to treat patients with hepatitis C non-responding to antiviral therapy ?” White Night of
Hepatology, St Petersburg, Russia, 2010.
44.- ”Alcoholic hepatitis: identification of new targets for therapy”. NIAAA, NIH, Bethesda, 2010.
45.- ”Alcoholic hepatitis: identification of new targets for therapy”. University of California at San
Diego, 2010.
46.- “APRI and Fibrotest: critical analysis of pros and cons”. Hepatologia do Milenio, Salvador
de Bahia, Brazil, 2010.
47.- “Human and experimental evidence supporting a role for osteopontin in the pathogenesis
of alcoholic liver disease”. International Society for Hepatic Sinusoid Research, Pasadena,
California, 2010.
21
48.- “Fibrogénesis hepática: mecanismos”. IV Congreso Nacional del Laboratorio Clínico.
Zaragoza, Spain, 2010.
49.- “Molecular mechanisms of liver fibrosis”. ISBRA World Congress, Paris, 2010.
50.- “Particular issues in transplantation for alcoholic and metabolic liver diseases”. 18th United
European Gastroenterology Week, Barcelona, 2010.
51.- “Alcoholic liver disease: mechanisms”. 18th United European Gastroenterology Week,
Barcelona, 2010.
52.- “Alcoholic hepatitis: identification of new targets for therapy. EASL Monothematic
Conference: Alcoholic Liver Disease”. Athens, Greece, 2010.
53.- “Genetic markers”. EASL Conference on Evaluation of Disease Severity and Prognosis in
Chronic Liver Disease. Nize, France, 2011.
54.- “Non-invasive liver fibrosis assessment”. Early Morning Workshop. EASL Annual Meeting,
Berlin, Germany, 2011.
55.- “Alcoholic hepatitis: identification of new targets for therapy”. University of North Carolina
at Chapel Hill, USA, 2011.
56.- “Alcoholic Liver Disease”. State-of-the-Art Lecture, Hepatologia do Milenio, Salvador de
Bahia, Brazil, 2011.
57.- “Opciones terapéuticas actuales y a futuro de la fibrosis hepática”. Curso de Nutricion,
Mexico DF, Mexico, 2012.
58. “Age as a risk factor for accelerated liver fibrosis: potential mechanisms”. Myoage,
59.- “Genes and Cirrhosis”. 9th International Meeting on Therapy in Liver Diseases, Barcelona,
Spain, 2012.
60.- “Alcoholic Liver Disease: an Update”. University of Arkansas, Little Rock, USA, 2012.
61. “New Therapeutic Targets for Alcoholic Hepatitis”, NIAAA Extramural Meeting on Alcoholic
Hepatitis, Bethesda, NIH, USA, 2012.
62.- “Alcoholic liver disease: novel targets for therapy”. King’s College, London, UK, 2012.
63.- “Concluding remarks: Alcoholic Liver Disease”. Co-director, Postgraduate Course. EASL
Anual Meeting, Barcelona 2012.
Awards:
1. "Premio de Ayuda al Estudio". Caja de Ahorros de Alicante.1986.
22
2.- "Beca de Introducción a la Investigación". Consejo Suerior de Investigaciones Científicas.
With the work entitled: "Diferenciación sexual del Sistema Nervioso Central" in the “Instituto de
Neurobiología Ramón y Cajal". Madrid. 1989.
3.- "Beca de Iniciación a la Investigación". Consellería de Cultura, Educació i Ciència de la
Generalitat Valenciana. “Determinación de HBV-DNA en hepatopatías crónicas virales tratadas
con Interferon a 2-recombinante". Valencia. 1990.
4.- “Beca predoctoral”. Consell Interdepartamental de Recerca i Tecnologia de la Generalitat
de Catalunya (CIRIT). Barcelona. 1996-1999.
5.- Beca final Residencia N°1 (Premio Emili Letang). Hospital Clínic of Barcelona. 1994.
6.- Best communication on portal hypertension, 32nd Annual Meeting of the European
Association for the Study of the Liver. London, 1997. R Bataller, P Ginès N, JM Nicolás, MN
Görbig, E Garcia-Ramallo, M Pinzani, V Arroyo, J Rodés. Human hepatic stellate contain
voltage-operated calcium channels.
7.- Best communication on portal hypertension, 34
th
Annual Meeting of the European
Association for the Study of the Liver. Napoli, 1999. N Görbig, P Ginès, R Bataller, E GarciaRamallo, J Ros, W Jiménez, JM Nicolás, V Arroyo, J Rodés. Human hepatic stellate cels
release the vasodilator peptide adrenomedullin. Potential autocrine factor in the regulation of
stellate cell contractility.
8.- Best poster presentation, 34th Annual Meeting of the European Association for the Study of
the Liver. Napoli, 1999. R Bataller, P Ginès, X Gasull, MN Görbig, E Garcia-Ramallo, JM
Nicolás, A Gual, V Arroyo, J Rodés. Phenotypic transformation of hepatic stellate cells into
myofibroblasts results in the expression of voltage-operated calcium channels.
9. Premio extraordinario de la Tesis Doctoral, Facultat de Medicina, Universitat de Barcelona,
2000.
10.- “Beca de la Asociación Española para Estudio de las Enfermedades del Hígado” for
postdoctoral stay in USA. Madrid, Spain, 2000-2002.
23
11.- Postdoctoral Research Fellowship Award from the American Liver Foundation.
“Investigation of the cellular and molecular mechanisms of hepatitic C virus-induced liver
fibrosis”. Chapel Hill, NC, USA, 2003.
Grant support:
1.- " ENFERMEDAD HEPÁTICA EN PACIENTES CON CONSUMO DE RIESGO DE
ALCOHOL: IDENTIFICACIÓN LOS FACTORES GENÉTICOS Y AMBIENTALES Y DE
NUEVAS DIANAS TERAPÉUTICAS". GRANT FROM THE SPANISH MINISTRY OF
SCIENCE AND INNOVATION (FIS). PRINCIPAL INVESTIGATOR. 2012-2014. €
312,000.
2.- “HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)”. EUROPEAN UNION
(HEALTH-2010-4.2.9-2). CO-INVESTIGATOR. 2011-2014. € 276,801.
3.- ”DEVELOPMENT OF A GENETIC TEST TO PREDICT THE PROGRESSION OF
LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C”. GRANT FROM THE
SPANISH MINISTRY OF SCIENCE AND INNOVATION (PET2008_0304). PRINCIPAL
INVESTIGATOR. 2009-2011. € 121,000.
4. “INVESTIGACIÓN TRASLACIONAL EN PACIENTES CON HEPATOPATÍAS
CRÓNICAS: DESARROLLO DE MÉTODOS PRONÓSTICOS E IDENTIFICACIÓN DE
NUEVAS DIANAS TERAPÉUTICAS”. GRANT FROM THE SPANISH MINISTRY OF
SCIENCE AND INNOVATION (FIS). PRINCIPAL INVESTIGATOR. 2009-2011. €
135,762.
5. “DEVELOPMENT OF INNOVATIVE ASSAYS AND LOCALLY ACTING THERAPIES
AIMING AT CRITICAL KINASES IN HEPATIC AND RENAL FIBROSIS (DIALOK)”.
EUROPEAN UNION (FP6-2005-LIFESCIHEALTH-7). INVESTIGATOR. 2006-2009. €
270,000.
6. “CELLULAR AND MOLECULAR MECHANISMS OF HEPATITIS C-INDUCED LIVER
FIBROSIS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND
INNOVATION (SAF). PRINCIPAL INVESTIGATOR. 2005-2008. € 121.000
7.- “ANGIOTENSIN II AND NADPH OXIDASE IN HEPATIC FIBROSIS”. NIH GRANT
(1R01DK072237-01). COLLABORATOR. 2004-2008.
8.- “HEPATIC STELLATE CELL ACTIVATION INDUCED BY HEPATITIS C VIRUS”.
NIH GRANT (5 R01 AA015955DK-03-011). CO-INVESTIGATOR. 2003-2007. € 60.000
9.- “CONTRACTILE AND FIBROGENIC FUNCTIONS OF HEPATIS STELLATE
CELLS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION
(SAF2002-03696). INVESTIGATOR. 2000-2002.
24
10.- “PROINFLAMMATORY AND FIBROGENIC FUNCTIONS OF HEPATIC
STELLATE CELLS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND
INNOVATION (SAF99-0014). INVESTIGATOR. 1997-1999.
Doctoral thesis:
1.- Sancho-Bru P. “Role of Vasocactive Substances in Hepatic Fibrosis”. 2006.
2.- Domínguez M. “Alcoholic Hepatitis: Pathogenic Basis and Prognostic Factors”. 2009.
3.- Colmenero J. “Gene Expression Analysis for the Ideentification of Therapeutic Targets and
Response to Therapy in Patients with Liver Fibrosis”. 2009.
4.- Moreno M. “Research of Novel Therapies for Liver Inflammation and Fibrosis”. 2010.
25

Curriculum Vitae - UNC Gillings School of Global Public Health

Transcripción

Documentos relacionados

PREMIOS «A TU SALUD» DE LA RAZÓN